Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $205.00 short put and a strike $200.00 long put offers a potential 38.5% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $205.00 by expiration. The full premium credit of $1.39 would be kept by the premium seller. The risk of $3.61 would be incurred if the stock dropped below the $200.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 54.2 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
How Amgen Could Take A Hammer To Sales Of Alexion's Biggest Drug
Fri, 30 Aug 2019 20:33:35 +0000
Alexion Pharmaceuticals stock crashed Friday after officials agreed to review Amgen's challenge to patents covering Alexion's blockbuster drug, Soliris, which treats several rare diseases.
Amgen drug patent challenge slices $2B off Alexion's market cap
Fri, 30 Aug 2019 15:33:27 +0000
Alexion's finances rely heavily on its rare disease drug Soliris. The drug is the source of 80 percent of Alexion's annual revenue.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
Fri, 30 Aug 2019 10:48:10 +0000
Style Box ETF report for DEF
Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer
Thu, 29 Aug 2019 15:24:03 +0000
Roche (RHHBY) wins EU approval for its immuno-oncology drug Tecentriq in combination with Abraxane to treat metastatic triple-negative breast cancer, which is a difficult-to-treat disease.
Amgen (AMGN) Up 11.2% Since Last Earnings Report: Can It Continue?
Thu, 29 Aug 2019 13:31:01 +0000
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Also on Market Tamer…
Follow Us on Facebook